Influence of canonical Wnt signaling pathway on the occurrence and development of ovarian cancer

Abstract

Abstract:The canonical Wnt signaling pathway has been the hot spot in the signaling pathway studies which are related to ovary carcinogenesis in recent years, whose activation may induce the multiplication and selfrenewal, survival and metastasis of ovarian cancer stem cells. The target gene mutations of key members in the canonical Wnt pathway and abnormal expresses of negative regulation molecules are closely associated with the occurrence and development of ovarian cancer. Deeply investigating the regulative mechanisms of canonical Wnt signaling pathway in ovarian cancer, and taking this as the therapeutic target to conduct the basic research and preclinical experiment may provide theoretical basis for treating better ovarian cancer patients in clinical practice.

Key words:Ovarian neoplasms,Beta catenin,Cadherins,Signal transduction

LIU Cui-Lian, CUI Cheng, WANG Li-Fei, HAO Shu-Wei. Influence of canonical Wnt signaling pathway on the occurrence and development of ovarian cancer[J]. Journal of International Oncology, 2014, 41(11): 844-847.

References

［1］ Bovicelli A, D′Andrilli G, Giordano A. New players in ovarian cancer［J］. J Cell Physiol， 2011, 226(10):25002504. ［2］ Zhou L, Graves M, MacDonald G, et al. Microenvironmental Regulation of BRCA1 Gene Expression by cJun and Fra2 in Premalignant Human Ovarian Surface Epithelial Cells［J］. Mol Cancer Res， 2013, 11(3):272281. ［3］张鑫馨，邵淑丽. β连环素及E钙黏附素在上皮性卵巢肿瘤中的表达及临床意义［J］. 中国医疗前沿， 2011, 6(2):4344. ［4］ Malanchi I, Peinado H, Kassen D, et al. Cutaneous cancer stem cell maintenance is dependent on betacatenin signaling［J］. Nature， 2008, 452(7187):650653. ［5］ Zhang Y, Piao BK, Zhang Y, et al. Oxymatrine diminishes the side population and inhibits the expression of βcatenin in MCF7 breast cancer cells［J］. Med Oncol， 2011, 28 Suppl 1:S99107. ［6］ Siu MKY, Wong ESY, Kong DSH, et al. Stem cell transcription factor NANOG controls cell migration and invasion via dysregulation of Ecadherin and FoxJ1 and contributes to adverse clinical outcome in ovarian cancers［J］. Oncogene， 2013, 32(30):35003509. ［7］ Chau WK, Ip CK, Mak AS, et al. cKit mediates chemoresistance and tumorinitiating capacity of ovarian cancer cells through activation of Wnt/betacateninATPbinding cassette G2 signaling［J］. Oncogene， 2013, 32(22):27672781. ［8］ Schmid S, Bieber M, Zhang F, et al. Wnt and hedgehog gene pathway expression in serous ovarian cancer［J］. Int J Gynecol Cancer， 2011, 21(6):975980. ［9］ Notaridou M, Quaye L, Dafou D, et al. Common alleles in candidate susceptibility genes associated with risk and development of epithelial ovarian cancer［J］. Int J Cancer， 2011, 128(9):20632074. ［10］ Dimova I, Orsetti B, Negre V, et al. Genomic markers for ovarian cancer at chromosomes 1, 8 and 17 revealed by array CGH analysis［J］. Tumori， 2009, 95(3): 357366. ［11］ Fan X, Liu Y, Jiang J, et a1. miR20a promotes proliferation and invasion by targeting APP in human ovarian cancer cells［J］. Acta Biochim Biophys Sin， 2010, 42(5):318324. ［12］ Sun X, He Y, Huang C, et al. Distinctive microRNA signature associated of neoplasms with the Wnt/βcatenin signaling pathway［J］. Cell Signal， 2013, 25(12):28052811. ［13］ Hudson LG, Zeineldin R, Stack MS. Phenotypic plasticity of neoplastic ovarian epithelium: unique cadherin profiles in tumor progression［J］. Clin Exp Metastasis， 2008, 25(6):643655. ［14］ DiMeo TA, Anderson K, Phadke P, et al. A novel lung metastasis signature links Wnt signaling with cancer cell selfrenewal and epithelialmesenchymal transition in basallike breast cancer［J］. Cancer Res， 2009, 69(13):53645373. ［15］ Stawerski P, WagrowskaDanilewicz M, Stasikowska O, et al. Immunoexpression of betacateninEcadherin complex in primary serous ovarian tumors［J］． Pol J Pathol， 2008, 59(1):2732. ［16］魏德娥，仲文玉，魏树珍，等． βcatenin、 Ecadherin、 APC在卵巢上皮性肿瘤中的表达［J］.山东大学学报(医学版)， 2011, 49(5):7174. ［17］ Yan X, Lyu T, Jia N, et al. Huaier Aqueous Extract Inhibits Ovarian Cancer Cell Motility via the AKT/GSK3β/βcatenin Pathway［J］. PLoS One， 2013, 8(5):e63731. ［18］ Ford CE, Jary E, Ma SS, et al. The Wnt gatekeeper SFRP4 modulates EMT, cell migration and downstream Wnt signalling in serous ovarian cancer cells［J］. PLoS One， 2013, 8(1)：e54362. ［19］ Barbolina MV, Burkhalter RJ, Stack MS, et al. Diverse mechanisms for activation of Wnt signalling in the ovarian tumour microenvironment［J］. Biochem J， 2011, 437(1):112. ［20］ Pu P, Zhang Z, Kang C, et al. Downregulation of Wnt2 and betacatenin by siRNA suppresses malignant glioma cell growth［J］. Cancer Gene Ther， 2009, 16(4):351361. ［21］ Wang J, Cai J, Han F, et al. Silencing of CXCR4 blocks progression of ovarian cancer and depresses canonical Wnt signaling pathway［J］. Int J Gynecol Cancer， 2011, 21(6):981987. ［22］ Veeck J, Dahl E. Targeting the Wnt pathway in cancer: the emerging role of Dickkopf3［J］. Biochim Biophys Acta， 2012, 1825(1):1828. ［23］ Yoshioka S, King ML, Ran S, et al. WNT7A regulates tumor growth and progression in ovarian cancer through the WNT/βcatenin pathway［J］. Mol Cancer Res， 2012, 10(3):469482.

[1]	Gong Yan, Chen Honglei.Research progress on the mechanism of microRNA regulation of cisplatin resistance in ovarian cancer[J]. Journal of International Oncology, 2024, 51(3): 186-190.
[2]	An Rong, Liu Meihua, Wang Peichen, Wang Xiaohui.Research progress of Nrf2 in ovarian cancer[J]. Journal of International Oncology, 2023, 50(8): 493-497.
[3]	Wu Minhang, Sun Wenzheng, Yu Qingzhuo, Guo Rong, Ye Hui, Du Ying, Qiu Jin, An Huazhang, Cao Lili.RNF43 inhibits PD-L1 expressionviaβ-catenin in melanoma cells and promotes CD8⁺T cell-mediated anti-tumor immune reaction[J]. Journal of International Oncology, 2023, 50(7): 407-412.
[4]	Li Chenxi, Zhao Hongwei.Prognosis and influencing factors of platinum sensitive recurrent ovarian cancer treated by secondary cytoreduction surgery in patients with unsatisfactory primary cytoreduction surgery[J]. Journal of International Oncology, 2023, 50(6): 342-347.
[5]	Yang Lirong, Wang Yufeng.Construction of machine learning models for predicting the risk of postoperative distant metastasis recurrence in serous ovarian cancer[J]. Journal of International Oncology, 2023, 50(4): 220-226.
[6]	Wang Qian, Tan Xiaojun, Zhang Donghui, Luo Kai.Application of β-catenin, Cyclin D1 and DKK1 in pathologically aided diagnosis of breast cancer[J]. Journal of International Oncology, 2021, 48(7): 402-408.
[7]	Li Chenxi, Zhao Hongwei.Advances in the treatment of platinum-resistant ovarian cancer with PARP inhibitors[J]. Journal of International Oncology, 2021, 48(3): 180-183.
[8]	Li Zhefeng, Li Jie, Zhao Xiaoting, Yue Wentao.GLDC regulates proliferation and apoptosis of ovarian cancer cells through PI3K/Akt/mTOR pathway[J]. Journal of International Oncology, 2021, 48(12): 716-722.
[9]	Zheng Jing, Yao Sheng, Shen Wenjie, Sun Zhijia, Zhao Hui, Fu Yan, Gao Ke, Du Nan.Clinical study of intraperitoneal infusion of bevacizumab combined with albumin paclitaxel and carboplatin in carcinomatous peritoneal adhesion from ovarian cancer[J]. Journal of International Oncology, 2021, 48(11): 660-665.
[10]	Yang Lifen, Song Wei, Xu Dawei, Wu Jun, Gao Ran.Mechanisms of miR-103a-3p/CHI3L1 in proliferation and vascular mimicry of ovarian cancer cells[J]. Journal of International Oncology, 2020, 47(6): 333-339.
[11]	Xue Chen, Zhao Yue, Shi Guang, Tang Yan.Research progress of PD-1/PD-L1 inhibitors in ovarian cancer[J]. Journal of International Oncology, 2020, 47(5): 312-315.
[12]	Yang Yiting, Cheng Zhongping.The role of inflammatory cytokines in chemoresistance of epithelial ovarian cancer[J]. Journal of International Oncology, 2020, 47(4): 249-251.
[13]	Fan Yangyang, Wang Ying, Yuan Feng, Du Shanping, He Rongrong, Jia Yan.Study on the mechanism of MALAT1 targeting miR-142-3p in ovarian cancer chemotherapy resistance[J]. Journal of International Oncology, 2020, 47(2): 82-89.
[14]	Quan Ruiquan, Zhang Li, Kuang Li, Li Hongbo, Xiao Meixian.Efficacy of olaparib combined with bevacizumab in the treatment of patients with recurrent platinum-sensitive ovarian cancer and its effect on serum HE4, CA125 and CTC levels[J]. Journal of International Oncology, 2020, 47(10): 606-610.
[15]	Zhang Haili, Li Juanfang, Li Xiaoqing, Shi Linjie, Li Yuanfei.CCR6 promotes liver metastasis of colorectal cancer through epithelial-mesenchymal transition[J]. Journal of International Oncology, 2020, 47(1): 29-34.